Sirolimus Eluting ORSIRO Stent Versus Biolimus-eluting NOBORI Stent (SORT OUT VII)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01879358|
Recruitment Status : Active, not recruiting
First Posted : June 17, 2013
Last Update Posted : September 23, 2016
|Condition or disease||Intervention/treatment||Phase|
|Coronary Artery Disease Ischemic Heart Disease||Device: Drug-eluting stent||Not Applicable|
SORT OUT VII is a randomized, multicenter, all-comer, two-arm, non-inferiority trial comparing the sirolimus eluting ORSIRO stent to the biolimus-eluting NOBORI stent in treating atherosclerotic coronary artery lesions.
Target lesion failure within 12 months of stent implantation (combination of cardiac death, myocardial infarction (not index procedure related) not related to other than index lesion or target lesion revascularization).
Individual components of the primary end point comprised the secondary end points and stent thrombosis rate according to the Academic Research Consortium definition (see protocol for further specification of secondary endpoints).
Clinically driven event detection will be used to avoid study-induced reinterventions. Data on mortality, hospital admission, coronary angiography, repeat percutaneous coronary intervention, and coronary bypass surgery will be obtained for all randomly allocated patients from the following national Danish administrative and healthcare registries: the Civil Registration System; the Western Denmark Heart Registry; the Danish National Registry of Patients, which maintains records on all hospitalizations in Denmark; and the Danish Registry of Causes of Death
at least 18 years old chronic stable coronary artery disease or acute coronary syndromes at least one coronary artery lesion with more than 50% diameter stenosis requiring treatment with a drug-eluting stent
life expectancy of less than one year allergy to aspirin, clopidogrel, sirolimus, or biolimus participation in another randomized trial nability to provide written informed consent
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||2314 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Randomized Comparison of a Sirolimus Eluting ORSIRO Stent With a Biolimus-eluting NOBORI Stent in Patients Treated With Percutaneous Coronary Intervention|
|Study Start Date :||November 2012|
|Actual Primary Completion Date :||February 2015|
|Estimated Study Completion Date :||February 2019|
Active Comparator: ORSIRO stent
ORSIRO stent group
Device: Drug-eluting stent
Active Comparator: NOBORI stent
NOBORI stent group
Device: Drug-eluting stent
- Cardiac death, myocardial infarction or target lesion revascularization [ Time Frame: 12 months ]Target lesion failure within 12 months of stent implantation (combination of cardiac death, myocardial infarction (not index procedure related) not related to other than index lesion or target lesion revascularization)
- Cardiac death, myocardial infarction, target lesion revascularization, target vessel revascularization, all cause mortality, stent thrombosis [ Time Frame: 12 months ]Cardiac mortality Myocardial infarction Target lesion revascularization Target vessel revascularization All cause mortality Stent thrombosis rate according to the Academic Research Consortium definition Secondary endpoints will be assessed after 1 year, 2 years, 3 years, 4 years and 5 years.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01879358
|Odense University Hospital|
|Odense, Denmark, 5000|
|Study Chair:||Jens F Lassen, MD DMSci||Aarhus University Hospital|